Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Cinnamtannin B1 (HB3838)
Description:Type A proanthocyanidine with many biological actions
Purity:>90%
Citrinin (HB3839)
Description:Mitochondrial permeability transition pore (MPTP) activator
Purity:>97%
Compound E (HB3849)
Description:Potent, selective, non-competitive γ-secretase inhibitor. Induces neuronal differentiation.
Purity:>98%
Cyclopamine (HB2965)
Description:Smo and hedgehog (Hh) signaling inhibitor. Also depletes stem like cancer cells and induces hESCs into endocrine cells.
Purity:>98%
Cyclosporin A (HB0220)
Description:Potent calcineurin inhibitor. Inhibits MPTP opening.
Purity:>99%